Lenacapavir, a long-acting injectable form of HIV prevention, is set to revolutionise HIV prevention strategies in South ...

Seattle and San Francisco scale back harm reduction policies distributing drug supplies, signaling a shift in how West Coast ...

President Trump’s anti-LGBTQ agenda dominated national news in 2025, particularly his cruel attacks on trans Americans. Here are our picks for the top 10 LGBTQ news stories the Blade covered in 2025.

Matthew Herper covers medical innovation — both its promise and its perils. It has been a tough year for medicine. The U.S.

The Wegovy pill is expected to hit the market in January, joining injectable GLP-1 drugs that have transformed obesity treatment. One form you swallow, the other you inject. What else is different?

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

The Trump administration's deep cuts in U.S. foreign health aid had a devastating impact. Yet there were achievements of note ...

The hope is by taking a pill only once a week, you're less likely to forget a dose, something that's critical when treating conditions like HIV.

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option ...

A daily preventive pill can be invaluable for people at risk for HIV. But some doctors don't know much about prescribing them. And billing headaches are common. Here's how to overcome those hurdles.

Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take antiretrovirals for HIV prevention over concerns about their impact on ...